MK-0431 Early Phase II Double-blind Study - Type 2 Diabetes Mellitus (0431-043)

Merck Sharp & Dohme (MSD)

Status and phase: Completed; Phase 2

Conditions: Type 2 Diabetes Mellitus

Treatments: Drug: Comparator : placebo (unspecified) / Duration of Treatment: 12 Weeks; Drug: MK0431, sitagliptin phosphate / Duration of Treatment: 12 Weeks

Study type: Interventional

Funder types: Industry

Identifiers

NCT00371007

2006_028

0431-043

Details and patient eligibility

About

A clinical study to determine the safety and efficacy of MK-0431 in patients with Type 2 diabetes mellitus who have inadequate glycemic control on diet/exercise therapy

Sex: All

Ages: 20 to 69 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients have type 2 diabetes mellitus
• On diet/exercise therapy

Exclusion criteria

• Patients have type 1 diabetes mellitus

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind